Kerr KM, et al. - In the ETOP Lungscape cohort of stage I-III non-small cell lung cancer (NSCLC), researchers examined the prevalence of PD-L1 positivity by performing immunohistochemistry on tissue microarrays, as well as focused on its relation to clinicopathological features, molecular profiles and patient outcome, including Relapse-free Survival, Time-to-Relapse and Overall Survival. From 15 ETOP centers, they examined 2182 NSCLC cases (2008 evaluable, median follow-up 4.8 years, 54.6% still alive) for PD-L1 expression. In more than one third of the Lungscape cohort (1%/5% cut-offs), the presence of PD-L1 positivity prevalence was found. A better prognosis was reported for non-metastatic adenocarcinoma patients in relation to PD-L1 positivity when adjusted for clinicopathological features.